Silver Book Fact

Effectiveness of an oral pharmacologic agent in preventing venous thrombosis

An oral pharmacologic agent has been demonstrated to be at least as effective as an injectable anticoagulant in the prevention of venous thrombosis following hip replacement.

Eriksson, BI, OE Dahl, N Rosencher, AA Kurth, CN van Dijk, SP Frostick, MH Prins, R Nettiarachchi, S Hantel, J Schnee, and HR Buller; for the RE-NOVATE Study Group. Dabigatran Etexilate Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Hip- Replacement: A randomised, double-blind, non-inferiority trial. Lancet. 2007; 370(9591): 949-56. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2807%2961445-7/fulltext

Reference

Title
Dabigatran Etexilate Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Hip- Replacement: A randomised, double-blind, non-inferiority trial
Publication
Lancet
Publication Date
2007
Authors
Eriksson, BI, OE Dahl, N Rosencher, AA Kurth, CN van Dijk, SP Frostick, MH Prins, R Nettiarachchi, S Hantel, J Schnee, and HR Buller; for the RE-NOVATE Study Group
Volume & Issue
Volume 370, Issue 9591
Pages
949-56
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • “Over the past thirty-five years, U.S. age-adjusted mortality from cardiovascular disease declined 50 percent. This marked reduction reflects advances in the prevention, diagnosis, and treatment of common cardiovascular conditions.”  
  • In 1996, fewer than 2 in 3 patients were receiving beta-blocker drugs to prevent a second heart attack. In 2006, more than 97% of heart attack patients received these treatments,…  
  • Per-patient annual cost of treating stroke in atrial fibrillation patients
    The per-patient annual cost of treating stroke in atrial fibrillation patients was found to be $1,485 in a wellcontrolled anti-coagulation clinic, $3,710 for those receiving warfarin in routine medical care,…  
  • Because of reduced mortality rates, the number of stroke survivors who are non-institutionalized increased from 2.0 to 2.4 million between 1980 and 1991.  
  • From 1970-2000, gains in longevity were greatest for people between the ages of 40 and 60, and greater for men than women, in large part because of advances in the…